RNA probe market seen reaching $2.92 billion by 2030

The RNA probe market is projected to grow from $2.08 billion in 2026 to $2.92 billion by 2030, as demand rises for molecular diagnostics, gene research and precision testing. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - RNA probes are a core tool for detecting, identifying and quantifying specific RNA targets in molecular diagnostics and research. - Demand is rising as genetic screening, cancer genomics, infectious disease testing and precision medicine expand. - The market’s growth signals broader adoption of high-specificity nucleic acid testing across clinical and research settings.

What happened: - The Business Research Company projected the global RNA probe market will grow from $2.08 billion in 2026 to $2.92 billion by 2030. - The forecast implies an 8.8% compound annual growth rate through 2030. - The company also estimated the market reached $1.91 billion in 2025 and $2.08 billion in 2026, a 9.3% CAGR in that period. - The report was released Sept. 22, 2026. - The company published a free sample report and the full market report.

The details: - RNA probes are short, single-stranded RNA sequences engineered to bind complementary nucleic acid strands. - The probes are used to detect, identify or quantify RNA targets. - They are often labeled with fluorescent, radioactive or enzymatic markers. - The report pointed to fluorescent and radiolabeled probe technologies as contributors to recent market growth. - It also cited increased use of in situ hybridization, cancer genomics, infectious disease testing and other highly specific detection methods. - The forecast to 2030 is supported by AI tools for probe design and sequence optimization. - The report also highlighted spatial transcriptomics, single-cell analysis, multiplexed assays and high-throughput probe formats. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The market analysis covered Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The growth forecast suggests RNA probes are moving from a specialized research tool to a more embedded part of precision diagnostics. - AI-assisted design and multi-omics workflows are likely to increase demand for faster and more accurate probe development. - The regional outlook points to mature demand in North America and faster adoption in markets investing in molecular diagnostics infrastructure. - Rising cystic fibrosis registrations in the UK reflect broader genetic disorder detection, which supports demand for RNA probes in clinical and research use. - Cystic Fibrosis Trust data showed UK patient registrations rose from 11,148 in 2022 to 11,381 in 2024.

What's next: - The market is expected to keep expanding as personalized medicine, precision diagnostics and molecular imaging gain traction. - Growth will likely track continued adoption of multiplexed, high-throughput assays and newer detection platforms. - Investments in genetic research and diagnostic capacity in Asia-Pacific could narrow the gap with North America over time.

The bottom line: - RNA probe demand is set to keep climbing through 2030, driven by diagnostics, research and technology upgrades.